Stem Cell Innovations to commercialize human embryonic germ cell platform in Europe

By Lisa Kerner

Erie, Pa., April 12 - Stem Cell Innovations, Inc. said it will commercialize the company's proprietary platform of human pluripotent stem cells in Europe through a newly established European research and development facility in Leiden, The Netherlands.

Stem Cell Innovations has produced multiple lines of human pluripotent stem cells, the first step in creating banks of cells to be matched to patients in cell therapies, according to a company news release.

The cells, produced without feeder layers (xenofree), can maintain their undifferentiated state and normal chromosome complement.

The company said it will produce stem cell lines in Leiden and Houston, Texas, in order to serve the European academia markets.

Stem Cell Innovations, through its wholly owned subsidiary, Amphioxus Cell Technologies based in Houston, is a cell biology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.